- Home
- FBIO vs CLNN Comparison
FBIO vs CLNN Comparison
Compare FBIO & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBIO | CLNN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | 78 | 79 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBIO | CLNN |
|---|---|---|
| Price | $2.27 | $6.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 462.7K | 81.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.22 | $17.64 |
| Revenue Next Year | $40.55 | $19,516.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $2.28 |
| 52 Week High | $4.53 | $13.50 |
Technical Indicators
Market Signals| Indicator | FBIO | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 51.41 |
| Support Level | $2.20 | $5.59 |
| Resistance Level | $2.71 | $6.83 |
| Average True Range (ATR) | 0.12 | 0.50 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 16.67 | 16.91 |
Price Performance
Historical ComparisonAbout FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.